Overview

A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The principal aim of this study is to obtain safety and tolerability data when PXT002331 is administered orally as single and multiple doses to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Prexton Therapeutics